➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Medtronic
Harvard Business School
Moodys
Express Scripts

Last Updated: April 20, 2021

DrugPatentWatch Database Preview

Cefuroxime sodium - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for cefuroxime sodium and what is the scope of freedom to operate?

Cefuroxime sodium is the generic ingredient in seven branded drugs marketed by B Braun, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira Inc, Teva Pharms, Watson Labs Inc, Samson Medcl, Acs Dobfar, Lilly, and Teligent, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are sixty-two drug master file entries for cefuroxime sodium. Three suppliers are listed for this compound.

Summary for cefuroxime sodium
US Patents:0
Tradenames:7
Applicants:11
NDAs:20
Drug Master File Entries: 62
Suppliers / Packagers: 3
Bulk Api Vendors: 73
Clinical Trials: 3
Patent Applications: 1,261
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in cefuroxime sodium?cefuroxime sodium excipients list
DailyMed Link:cefuroxime sodium at DailyMed
Recent Clinical Trials for cefuroxime sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital Universitari Vall d'Hebron Research InstitutePhase 4
University Hospital, Basel, SwitzerlandPhase 4
PriCara, Unit of Ortho-McNeil, Inc.Phase 2/Phase 3

See all cefuroxime sodium clinical trials

Pharmacology for cefuroxime sodium

US Patents and Regulatory Information for cefuroxime sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INJECTION 065484-001 Oct 15, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Pharms CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 064192-002 Apr 16, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Teligent ZINACEF IN PLASTIC CONTAINER cefuroxime sodium INJECTABLE;INJECTION 050643-001 Apr 28, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs Inc CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 064035-001 Feb 26, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Teligent ZINACEF cefuroxime sodium INJECTABLE;INJECTION 050558-004 Oct 23, 1986 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
McKinsey
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.